Therefore, it is reasonable to speculate that pharmacological strategies able to overcome resistance and/or restore responsiveness to IL-10, as happens by the treatment with a small molecule agonist of SHIP1 (Src homology-2 containing inositol-5’-phosphatase 1) in macrophages under hyperglycemia (151), could give a valid therapeutic opportunity to reduce the overwhelmed inflammation in patients with severe COVID-19, especially those with diabetes. Here, IL10 is linked to diabetes mellitus.